Glaucia Tobaldini

Glaucia Tobaldini

Auto-generated profile, based on publicly available information

Glaucia Tobaldini

Department of Physiology, Division of Biological Sciences, Federal University of Parana, Curitiba, Parana, Brazil

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 September 2017 in Pain
Verified
Journal Article
Closed access
PDF file
NSNatalia Fantin Sardi
Natalia Fantin Sardi
GTGlaucia Tobaldini
Glaucia Tobaldini
RMRosana Nogueira Morais
Rosana Nogueira Morais
LFLuana Fischer
Luana Fischer
Sleep disorders increase pain sensitivity and the risk of developing painful conditions; however, the underlying mechanisms are poorly understood. It has been suggested that nucleus accumbens (NAc) influences sleep-wake cycle by means of a balance between adenosine activity at A2A receptors and dopamine activity at D2 receptors. Because the NAc also plays an important role in pain modulation, we hypothesized that the NAc and its A2A and D2 receptors mediate the pronociceptive effect of rapid eye movement (REM) sleep deprivation (SD). We found that 24 hours of REM-SD induced an intense pronociceptive effect in Wistar rats, which decreases progressively over a sleep rebound period. Although the level of fecal glucocorticoid metabolites increased with SD within group, it did not differ between sleep-deprived group and control group, indicating a stress response with similar magnitude between groups. The pronociceptive effect of REM-SD was prevented by excitotoxic lesion (N-Methyl-D-aspartate, 5.5 μg) of NAc and reverted by its acute blockade (Qx-314, 2%). The administration of an A2A receptor antagonist (SCH-58261, 7 ng) or a D2 receptor agonist (piribedil, 6 μg) into the NAc increased home cage activity and blocked the pronociceptive effect of REM-SD. Complementarily, an A2A receptor agonist (CGS-21680, 24 ng) impaired the reversal of the pronociceptive effect and decreased home cage activity, as it did a D2 receptor antagonist (raclopride, 5 μg). Rapid eye movement SD did not affect the expression of c-Fos protein in NAc. These data suggest that SD increases pain by increasing NAc adenosinergic A2A activity and by decreasing NAc dopaminergic D2 activity.

24 February 2015 in Molecular Neurobiology
Verified
Journal Article
Closed access
PDF file
DTDabna H. Tomim
Dabna H. Tomim
FPFelipe M. Pontarolla
Felipe M. Pontarolla
JBJessica F. Bertolini
Jessica F. Bertolini
MAMauricio Arase
Mauricio Arase
GTGlaucia Tobaldini
Glaucia Tobaldini
LFLuana Fischer
Luana Fischer

1 June 2018 in Molecular Neurobiology
Verified
Journal Article
Closed access
PDF file
GTGlaucia Tobaldini
Glaucia Tobaldini
NSNatalia F. Sardi
Natalia F. Sardi
VGVinicius A. Guilhen
Vinicius A. Guilhen
LFLuana Fischer
Luana Fischer

1 September 2018 in Neuropharmacology
Verified
Journal Article
Closed access
NSNatalia F. Sardi
Natalia F. Sardi
MLMayla K. Lazzarim
Mayla K. Lazzarim
VGVinicius A. Guilhen
Vinicius A. Guilhen
RMRenata S. Marcílio
Renata S. Marcílio
PNPriscila S. Natume
Priscila S. Natume
LFLuana Fischer
Luana Fischer

1 April 2014 in The Journal of Pain
Verified
Journal Article
Closed access
GTGlaucia Tobaldini
Glaucia Tobaldini
BABetina Aisengart
Betina Aisengart
MLMarcelo M.S. Lima
Marcelo M.S. Lima
CTClaudia H. Tambeli
Claudia H. Tambeli
LFLuana Fischer
Luana Fischer

1 April 2018 in Behavioural Pharmacology
Verified
Journal Article
Closed access
GTGlaucia Tobaldini
Glaucia Tobaldini
RRRafael A. Reis
Rafael A. Reis
NSNatalia F. Sardi
Natalia F. Sardi
MLMayla K. Lazzarim
Mayla K. Lazzarim
DTDabna H. Tomim
Dabna H. Tomim
LFLuana Fischer
Luana Fischer
As important as perceiving pain is the ability to modulate this perception in some contextual salient situations. The periaqueductal gray (PAG) is perhaps the most important site of endogenous pain modulation; however, little is known about dopaminergic mechanisms underlying PAG-mediated antinociception. In this study, we used a pharmacological approach to evaluate this subject. We found that µ-opioid receptor-induced antinociception (DAMGO, 0.3 μg) from PAG was blocked by the coadministration of either D1-like or D2-like dopaminergic antagonists (SCH23390, 2, 4, and 6 μg or raclopride, 2 and 4 μg, respectively) both in the tail-flick and in the mechanical paw-withdrawal test. A selective D2-like receptor agonist (piribedil, 6 and 12 μg into the PAG) induced antinociception in the mechanical paw-withdrawal test, but not in the tail-flick test. This effect was blocked by the coadministration of its selective antagonist (raclopride 4 μg), as well as by either a GABAAagonist (muscimol, 0.1 μg) or an opioid receptor antagonist (naloxone, 0.5 μg). A selective D1-like receptor agonist (SKF38393, 1, 5, and 10 μg into the PAG) induced a poor and transient antinociceptive effect, but when combined with piribedil, a potentiated antinociceptive effect emerged. None of these treatments affected locomotion in the open-field test. These findings suggest that µ-opioid antinociception from the PAG depends on dopamine acting on both D1-like and D2-like receptors. Selective activation of PAG D2-like receptors induces antinociception mediated by supraspinal mechanisms dependent on inhibition of GABAAand activation of opioid neurotransmission.